Generic Drug Price-Fixing: New $17.8M Payout and How to Claim Your Share

HARTFORD, Conn. – March 17, 2026 – Millions of American consumers who may have paid inflated prices for common generic prescription drugs are a step closer to receiving compensation, as state officials announced new settlements totaling nearly $17.8 million. The agreements with drug manufacturers Bausch Health US, LLC, Bausch Health Americas, Inc., and Lannett Company, Inc. mark the latest development in a sprawling multi-state legal battle against alleged industry-wide price-fixing.

Led by the Connecticut Attorney General's office, the lawsuits claim that numerous generic drug makers unlawfully conspired with each other to artificially inflate and fix the prices of hundreds of medications. This alleged anti-competitive behavior meant that individuals, insurers, and government programs may have overpaid for essential medicines for years. The current settlements bring the total recovered in civil actions to well over $500 million, with funds earmarked for consumer restitution.

The Broader Battle Against Big Pharma

While the $17.8 million settlement provides a measure of relief, it represents just one front in a massive legal war. This litigation is part of a consolidated case known as Multidistrict Litigation (MDL) 2724, which combines lawsuits from a coalition of more than 40 states and territories. First filed in 2016, the case alleges that for over a decade, some of the biggest names in the generic drug industry engaged in a widespread conspiracy to allocate markets and coordinate price increases for over 100 different drugs.

The scale of the alleged misconduct is vast, and these new settlements follow several other significant resolutions. Previously, companies like Heritage Pharmaceuticals and Apotex Corp. settled for a combined $49.1 million. Industry giants have also faced enormous penalties. Sandoz, a major player, has agreed to pay over $500 million across separate settlements with different plaintiff groups. Teva Pharmaceuticals, another key defendant, entered a deferred prosecution agreement with the U.S. Department of Justice, agreeing to a $225 million criminal penalty and other concessions for its role in the price-fixing schemes.

With a major trial against the remaining non-settling defendants anticipated in late 2026, state attorneys general are signaling their long-term commitment to pursuing the case to its fullest extent. The list of companies still under litigation includes major industry players like Mylan (now part of Viatris), Pfizer, and Taro, indicating the fight is far from over.

Are You Owed Money? Eligibility and Next Steps

For consumers, the most pressing question is whether they are eligible for a payout. According to the Attorney General's office, you may be included if you meet several criteria:

• You purchased a generic prescription drug manufactured by any of the named defendants.
• The drug is one of the specific medications included in the lawsuit.
• The purchase was made between May 1, 2009, and December 31, 2019.
• You resided in a participating state or U.S. territory (including Washington, D.C.) at the time of purchase.

Of the new $17.8 million settlement, approximately $12.6 million is designated for direct distribution to consumers, with the remainder covering administrative and legal costs. This money will be added to a larger Settlement Fund that includes money from past and future settlements.

Crucially, the claims process is not yet open. Officials have established a central resource for consumers to stay informed. To receive updates, including when claim forms become available, individuals are strongly encouraged to register at the official settlement website, AGGenericDrugs.com, or call the toll-free number at 1-866-290-0182. The website will provide a full list of the drugs involved and detailed eligibility requirements.

Consumers also have specific rights and deadlines. If you wish to retain your right to sue the settling companies independently, you must formally "opt out" of the settlement by May 6, 2026. Objections or comments on the settlement must also be submitted by that date. A court will hold a final approval hearing for the current settlements on May 27, 2026.

Spotlight on the Accused

The companies involved in this latest settlement have faced scrutiny before. Lannett Company, Inc. has a documented history of facing anti-competitive allegations. In 2016, news broke that the company could face criminal charges for price collusion, leading to shareholder lawsuits alleging that executives had misled investors about the sustainability of its pricing strategies while engaging in anti-competitive agreements.

Bausch Health, a multinational pharmaceutical giant with over $10 billion in annual revenue, is also a defendant in the wider litigation. While a significant player in the market, the company carries a substantial debt load, and this settlement resolves one of its ongoing legal challenges.

The continued litigation against non-settling defendants underscores the pervasive nature of the allegations. Many of these companies, while denying wrongdoing, have already paid hundreds of millions in fines and settlements related to separate but similar claims from the Department of Justice and other plaintiff groups, painting a picture of an industry grappling with systemic issues of anti-competitive behavior.

Reshaping the Pharmaceutical Landscape

Beyond the financial payouts, the long-running generic drug price-fixing litigation is having profound, industry-wide ramifications. The core promise of generic drugs is to provide affordable alternatives to expensive brand-name medications. These lawsuits allege that this promise was betrayed by a coordinated effort to subvert market competition for profit.

The aggressive enforcement by state attorneys general and the U.S. Department of Justice has placed the entire pharmaceutical industry under a microscope. This heightened scrutiny is forcing companies to re-evaluate their pricing strategies and bolster their internal compliance programs to avoid crippling fines and reputational damage. The legal actions serve as a powerful deterrent, sending a clear message that collusive behavior will be investigated and prosecuted.

Ultimately, these efforts aim to restore integrity and true competition to the generic drug market. As the legal battle continues against the remaining defendants, with a major trial looming, these settlements serve as both a victory for consumer protection and a stark reminder of the continuous oversight required to ensure the promise of affordable generic medicine becomes a reality for all Americans.